We invest exclusively in tech-enabled healthcare services, healthcare information technology, and medical device and diagnostics companies. HLM is one of the nation’s oldest and most experienced venture firms dedicated to these sectors.
Over our careers, we have been responsible for financing, advising, and leading or co-leading liquidity events for more than 300 healthcare companies, and have been affiliated with many of the industry’s most successful and innovative emerging growth healthcare companies.
Ed Cahill, partner
Ed is currently a director of Binary Fountain, Carevive, Persivia, Phreesia (NYSE), and Tandem Diabetes (NASDAQ). Ed previously served as a director of Animas Corporation (acquired by J&J), Centene Corporation (NYSE), Masimo Corporation (NASDAQ), TYRX (acquired by Medtronic) and Vets First Choice, now Covetrus (NASDAQ).
He is a Trustee of Mercy Health Services, Johns Hopkins Medicine and chairs the board committee on patient safety and quality at Johns Hopkins Hospital.
Ed received an AB from Williams College and a Master of Public and Private Management degree from Yale University. He lives with his wife, Kate, in Dedham, Massachusetts.
Vin Fabiani, partner
Vin is a director at ClearDATA Networks, Prism Education and ReGroup Therapy, and a board observer at ArroHealth, Binary Fountain, Carevive, mPulse Mobile and Persivia. Vin is responsible for the firm’s Health Care Accelerator efforts and a mentor in Blueprint Health (www.blueprinthealth.org) and StartUp Health (www.startuphealth.com) programs, as well as a mentor/advisor to several companies including WellTrackOne and Mediquire.
Peter Grua, partner
Peter’s venture investment activity has been focused on healthcare services and healthcare information technologies. Peter is currently a director of Ampersand Health, Linkwell Health, MedOptions, meQuilibrium, Oceans Healthcare and OnShift. He previously served as a director of several companies including: The Advisory Board (NASDAQ acquired by Optum), Actamed (acquired by WebMD), ArroHealth (acquired by Ciox), Casenet (acquired by Centene), MedVentive (acquired by McKesson), Imagine Health (acquired by ELAP), Medicalis (acquired by Siemens Healthineers); Nordic Consulting (recapitalized by Silversmith), Sanovia (acquired by Health Information Designs), Silverlink Communications (acquired by Welltok), Atria Communities (NASDAQ), Renal Care Group (NYSE) and WellTower (aka Health Care REIT| NYSE).
Prior to joining HLM in 1992, Peter was a Managing Director of Alex. Brown & Sons, where he directed research in healthcare services and managed care. Previously, he was a research analyst at William Blair & Company and a strategy consultant at Booz Allen Hamilton.
Peter received an AB from Bowdoin College and an MBA from Columbia University.
Enrico Picozza, Partner
Enrico is a pioneer in the life sciences with a history of recognizing and developing new technologies that change markets. He is currently a director of AbleTo, mPulseMobile, RubiconMD and a board observer to OnShift. His previous board appointments included Vericare (Sold to MedOptions), Spinal Kenetics (Sold to Orthofix), Transend Medical (sold to Alcon), Medicalis (Sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic), and Tandem Diabetes (NASDAQ).
Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology.
Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker.
Enrico attended the University of Connecticut for undergraduate and post graduate studies in the major Molecular and Cell Biology.
Steve Tolle, partner
Steven Tolle has just joined HLM Venture Partners. He brings to HLM 30 years of commercial healthcare technology expertise in the areas of strategy, business development, and product management. Steve has spent his career helping to develop and manage some of the most important themes in healthcare innovation and investment today, including artificial intelligence, diagnostic imaging/medical devices, electronic health records, population health, managed care and value-based pharmaceutical pricing.
Prior to joining HLM, Steve was global Vice President of Strategy at IBM Watson Health. Previously, he was Chief Strategy Officer at Merge Healthcare (acquired by IBM for $1B in 2015). Steve led the effort to move Merge Healthcare into the AI space and played a key role in the successful sale to IBM. As part of the Merge/Watson Health leadership team, Steve worked on over $3.6 billion of strategic M&A deal opportunities.
Other notable previous roles include Senior Vice President/General Manager at Optum, Vice President of Product Management at Allscripts, and Director of Product Management at Pfizer.
Mike wong, Chief Financial Officer
Mike joined HLM in 2007 and was promoted to CFO in 2015. He provides the team with legal and diligence support and is responsible for the financial and administrative functions of the firm. Prior to joining HLM, he was a Financial Analyst at Summit Partners and a Senior Auditor at Deloitte. Mike received a BSBA in Accounting and Finance from Boston University and an MBA in Finance from Boston College. He is also a Certified Public Accountant.